Terug
Dagbereik
€ 8,64
€ 8,92
52-Weeksbereik
€ 8,50
€ 14,87
Volume
101.404
50D / 200D Gem.
€ 10,90
/
€ 11,14
Vorige Slotkoers
€ 8,68
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -5,3 | 0,4 |
| P/B | 1,7 | 2,9 |
| ROE % | -44,7 | 3,7 |
| Net Margin % | — | 3,9 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Hold
€ 21,67
+146.0%
Low: € 18,00
High: € 24,00
Forward WPA
-€ 2,18
Omzet Sch.
0
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
-€ 2,31
-€ 2,31 – -€ 2,31
|
17 M | 1 |
| FY2029 |
-€ 2,08
-€ 2,08 – -€ 2,08
|
0 | 1 |
| FY2028 |
-€ 2,13
-€ 2,47 – -€ 1,63
|
0 | 5 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 |
Mehra Uneek
Chief Financial Officer
|
grant | 128.330 | — | — |
| Mar 10, 2026 |
Beltran Pedro
Chief Scientific Officer
|
grant | 256.670 | — | — |
| Mar 10, 2026 |
Ben Yong
Chief Med & Dev Officer
|
grant | 256.670 | — | — |
| Jan 1, 2026 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1.114.400 | — | — |
| Dec 10, 2025 |
Wallace Eli M.
Chief Executive Officer
|
sell | 1.114.400 | — | — |
| Oct 10, 2025 |
BridgeBio Pharma LLC
|
other | 784.720 | — | — |
| Oct 2, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 1.614.400 | — | — |
| Aug 26, 2025 |
Mehra Uneek
Chief Financial Officer
|
grant | 633.570 | — | — |
| Aug 26, 2025 |
Ben Yong
Chief Med & Dev Officer
|
grant | 357.177 | — | — |
| Aug 26, 2025 |
Tipirneni Praveen P.
|
grant | 52.269 | — | — |
| Aug 26, 2025 |
Wallace Eli M.
Chief Executive Officer
|
grant | 499.731 | — | — |
| Aug 26, 2025 |
Bauer Jake
|
grant | 138.193 | — | — |
| Aug 26, 2025 |
Beltran Pedro
Chief Scientific Officer
|
grant | 357.177 | — | — |
| Aug 26, 2025 |
MCCORMICK FRANK
|
grant | 91.076 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
other | 8.344.252 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
sell | 460.814 | — | — |
| Aug 11, 2025 |
Chen Bihua
Director, 10% Owner
|
grant | 10.950.408 | € 10,72 | — |
| Aug 11, 2025 |
McKenna Mark C.
|
other | 60.000 | — | — |
| Aug 11, 2025 |
Schmid John P.
|
other | 60.000 | — | — |
| Aug 11, 2025 |
Holman Albert A III
|
other | 60.000 | — | — |
Belangrijkste Punten
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -114,50M
PEG of 0,00 suggests growth is underpriced
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-44,70%
ROIC-26,43%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
0,01
Current Ratio12,14
Interest Coverage0,00
Waardering
P/E Ratio
-5,26
P/B Ratio1,72
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -134,04M |
| ROE | -44,70% | ROA | -29,90% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -114,50M |
| ROIC | -26,43% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 12,14 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -5,26 | P/B Ratio | 1,72 |
| P/S Ratio | N/A | PEG Ratio | 0,00 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 705,09M | Enterprise Value | 334,17M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Net Income | -134,04M | -74,28M | -64,70M | -3.520,0 | -43.357,0 |
| EPS (Diluted) | -4,30 | 0,46 | 0,00 | 0,00 | 0,00 |
| Gross Profit | -610.000,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Operating Income | -145,82M | -80,86M | -64,77M | -3.520,0 | -43.357,0 |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448,38M | 194,42M | 332.894,0 | 144.578,0 | 144.281,0 |
| Total Liabilities | 37,29M | 5,71M | 396.463,0 | 166.455,0 | 162.638,0 |
| Shareholders' Equity | 411,10M | 188,72M | -63.569,0 | -21.877,0 | -18.357,0 |
| Total Debt | 2,77M | 0,0 | 70.095,0 | 43.106,0 | 36.961,0 |
| Cash & Equivalents | 373,69M | 1,70M | 0,0 | 0,0 | 0,0 |
| Current Assets | 425,46M | 1,95M | 0,0 | 0,0 | 0,0 |
| Current Liabilities | 35,04M | 187.515,0 | 396.463,0 | 166.455,0 | 162.638,0 |